Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide

Bone Marrow Transplantation volume 53, pages 1522–1531 (2018)Cite this article

Subjects

Abstract

The effects of graft or donor characteristics in haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PT-Cy) are largely unknown. In this multicenter retrospective study we analyzed the correlations between graft cell composition (CD34+, CD3+) and donor features on transplant outcomes in 234 patients who underwent HCT between 2010 and 2016. On multivariate analysis, the use of peripheral blood stem cells (PBSC) was associated with an increased incidence of grade 2–4 acute GVHD [HR 1.94, 95% confidence Interval (CI) = 1.01–3.98, p = 0.05]. An elevated CD3+ graft content was associated with an increased incidence of all-grade chronic GVHD [HR 1.36 (95% CI = 1.06–1.74), p = 0.01]. This effect was confirmed only for the PBSC graft group. A higher CD34+ graft content had a protective role on non-relapse mortality [HR 0.78 (95% CI = 0.62–0.96), p = 0.02] but this was confirmed only for the bone marrow (BM)-derived graft cohort. Donor characteristics did not influence any outcomes. GVHD prophylaxis should be modulated accordingly to CD3+ graft content, especially when a PBSC graft is used. These results need further validation in prospective trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–71.

    Article  CAS  Google Scholar 

  2. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Good RA, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet Lond Engl. 1981;2:327–31.

    Article  CAS  Google Scholar 

  3. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.

    Article  CAS  Google Scholar 

  4. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.

    Article  CAS  Google Scholar 

  5. O’Donnell P, Luznik L, Jones R, Vogelsang G, Leffell M, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.

    Article  Google Scholar 

  6. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

    Article  CAS  Google Scholar 

  7. Ciurea SO, Zhang M-J, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–40.

    Article  CAS  Google Scholar 

  8. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood . 2016;127:938–47.

    Article  CAS  Google Scholar 

  9. Bashey A, Zhang M-J, McCurdy SR, St. Martin A, Argall T, Anasetti C, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell–replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017;35(26):3002-3009.

    Article  CAS  Google Scholar 

  10. Mussetti A, Greco R, Peccatori J, Corradini P. Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand? Expert Rev Hematol. 2017;10:479–92.

    Article  CAS  Google Scholar 

  11. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–22.

    Article  CAS  Google Scholar 

  12. Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, et al. Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant. 2015;21:1506–14.

    Article  CAS  Google Scholar 

  13. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

    Article  Google Scholar 

  14. Sorror ML. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  Google Scholar 

  15. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood . 2012;120:905–13.

    Article  CAS  Google Scholar 

  16. Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48:S1–37.

    Article  Google Scholar 

  17. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood . 2015;125:1333–8.

    Article  CAS  Google Scholar 

  18. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    CAS  Google Scholar 

  19. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.

    Article  CAS  Google Scholar 

  20. Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood. 2003;102:1108–13.

    Article  CAS  Google Scholar 

  21. Martin PS, Li S, Nikiforow S, Alyea EP, Antin JH, Armand P, et al. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 + cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica . 2016;101:499–505.

    Article  CAS  Google Scholar 

  22. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013.

    Google Scholar 

  23. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. http://www.R-project.org/.

    Google Scholar 

  24. Waller EK, Logan BR, Harris WAC, Devine SM, Porter DL, Mineishi S, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results From BMTCTN 0201. J Clin Oncol. 2014;32:2365–72.

    Article  Google Scholar 

  25. Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, et al. High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2015;33:2392–8.

    Article  CAS  Google Scholar 

  26. Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20:1262–73.

    Article  Google Scholar 

  27. McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai H-L, Showel MM, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102:391–400.

    Article  CAS  Google Scholar 

  28. McCurdy SR, Kanakry JA, Showel MM, Tsai H-L, Bolanos-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024–31.

    Article  CAS  Google Scholar 

  29. Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:758–69.

    Article  Google Scholar 

  30. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–51.

    Article  CAS  Google Scholar 

  31. Wang Y, Chang Y-J, Xu L-P, Liu K-Y, Liu D-H, Zhang X-H, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood . 2014;124:843–50.

    Article  CAS  Google Scholar 

  32. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai H-L, Bolaños-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16:482–9.

    Article  CAS  Google Scholar 

  33. McCurdy SR, Zhang M-J, St. Martin A, Al Malki MM, Bashey A, Gaballa S, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018;2:299–307.

    Article  Google Scholar 

  34. Ruggeri A, Labopin M, Bacigalupo A, Gülbas Z, Koc Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018;124(7):1428-1437.

    Article  CAS  Google Scholar 

  35. Rubio M-T, Bouillié M, Bouazza N, Coman T, Trebeden-Nègre H, Gomez A, et al. Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease. Leukemia. 2017;31:903–12.

    Article  CAS  Google Scholar 

  36. McCurdy SR, Kanakry CG, Tsai H-L, Kasamon YL, Showel MM, Bolaños-Meade J, et al. Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2018;24:343–52.

    Article  CAS  Google Scholar 

  37. Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, et al. Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014;20:1418–25.

    Article  Google Scholar 

  38. Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood . 2009;114:2606–16.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

All patients and their families. Supported in part by Associazione Italiana contro le Leucemia-Linfomi e Mielomi (AIL).

Author contributions

Conception and design: A.M.; Financial support: none; Collection and assembly of data: All authors. Data analysis: A.M.; Interpretation: All authors. Manuscript writing: First draft prepared by A.M.; All authors helped in revising the manuscript. Final approval of manuscript: All authors

Author information

Authors and Affiliations

  1. Division of Hematology and Bone Marrow Transplant, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    A Mussetti, C Carniti & P Corradini

  2. Department of Hematology and Oncology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

    C De Philippis, J Mariotti & L Castagna

  3. Servicio de Hematología y Hemoterapia, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    M Bastos-Oreiro & J Gayoso

  4. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

    M Bastos-Oreiro & J Gayoso

  5. Dept. of Oncology and Hematology, University of Milano, Milan, Italy

    N Cieri, M Pennisi & P Corradini

  6. Hematology and Bone Marrow Transplantation (BMT) Unit, San Raffaele Scientific Institute, Milan, Italy

    F Ciceri, R Greco & J Peccatori

  7. Hematology, DAME, University Hospital, University of Udine, Udine, Italy

    F Patriarca

Authors
  1. A Mussetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C De Philippis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Carniti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Bastos-Oreiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Gayoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Cieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Pennisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Peccatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Patriarca
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Mariotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Mussetti.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mussetti, A., De Philippis, C., Carniti, C. et al. CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant 53, 1522–1531 (2018). https://doi.org/10.1038/s41409-018-0183-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0183-8

This article is cited by

Search

Advanced search

Quick links